Buy­out buzz hits fever pitch on re­port that Nek­tar is ‘ex­plor­ing op­tions’

The buzz about a pos­si­ble ac­qui­si­tion of Nek­tar Ther­a­peu­tics $NK­TR has been in­tense over the last few weeks, es­pe­cial­ly as new M&A deals have be­gun to pour through. So maybe it’s not a huge sur­prise to hear that Bloomberg is re­port­ing Fri­day af­ter­noon that the biotech is ex­plor­ing its op­tions, and per­haps a sale.

Nek­tar spot­light­ed NK­TR-214 at SITC last fall, rais­ing in­ter­est for a ther­a­py that hopes to make waves in I/O.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.